Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-06-17 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the listing and circulation of restricted shares that were previously subject to lock-up periods following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the shareholders involved, their commitments, and the regulatory approvals. The document references the stock code, lock-up expiration date, and compliance with securities regulations. It does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or management report. It is a formal announcement about the unlocking and circulation of restricted shares post-IPO, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share capital availability and trading status.
2022-06-17 Chinese
北京大成（长春）律师事务所关于长春百克生物科技股份公司2021年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 Annual General Meeting (AGM) of Changchun Baike Biotechnology Co., Ltd. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document focuses on the AGM process and the validation of the meeting's procedures and outcomes, rather than presenting the annual report itself or financial data. It is not a full annual report (10-K), nor an audit report, nor a voting results announcement alone. Instead, it is a legal opinion related to the AGM. Given the content and purpose, the document best fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions on the meeting.
2022-06-07 Chinese
长春百克生物科技股份公司2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a "2021 Annual General Meeting Resolution Announcement" for Changchun Baike Biotechnology Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2021 annual report, financial budget, profit distribution, and appointment of auditors. It also includes legal witness statements confirming the validity of the meeting and voting procedures. The document is an official announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or other detailed financial documents. The length is 3674 characters, which is relatively short and consistent with a voting results announcement. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-06-07 Chinese
长春百克生物科技股份公司2021年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the 2021 Annual General Meeting (AGM) materials for Changchun Baike Biotechnology Co., Ltd. It contains detailed agenda, meeting instructions, reports from the board of directors and supervisory board, and other materials prepared for the 2021 AGM held in June 2022. The content includes meeting procedures, voting instructions, and detailed reports to be presented and discussed at the AGM. There is no indication that this is the full Annual Report (10-K) or an earnings release, but rather the materials prepared specifically for the AGM. The document length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2022-05-26 Chinese
长春百克生物科技股份公司关于股票交易异常波动问询函的回函（实际控制人、控股股东）
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It states that the company has no undisclosed information that could significantly affect the stock price. The content is a regulatory reply to a stock exchange or regulatory body inquiry, typical of regulatory compliance communications. The document is short (404 characters) and does not contain financial statements, management discussion, or detailed financial data. It is not an annual report, earnings release, or any financial report. It is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-05-23 Chinese
长春百克生物科技股份公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Changchun Baike Biotechnology Co., Ltd. regarding abnormal stock price fluctuations over two trading days, with explanations and clarifications about the company's operations, media reports, and stock trading activities. It references stock exchange rules and regulatory requirements for disclosure but does not contain financial statements or detailed financial data. The document is relatively short (2132 characters) and serves as a regulatory disclosure about stock price movements and related company information. It is not an annual report, earnings release, or any detailed financial report. It fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about stock trading abnormalities and related clarifications.
2022-05-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.